Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg.".